SUNCT Syndrome

SUNCT is a rare headache condition. The name tells you the main features: Short-lasting, Unilateral (one-sided), Neuralgiform (sharp, electric-like) headache attacks with Conjunctival injection (the white of the eye turns red) and Tearing (the eye waters). An attack is usually very short, from a few seconds to a few minutes, and the pain stays on one side of the head, most often around the eye or temple. During the pain, the eye on the same side becomes red and watery, and there may be other “automatic” body responses on that side, like a stuffy or runny nose, a puffy eyelid, sweating, or flushing. Doctors group SUNCT within a family of headaches called trigeminal autonomic cephalalgias (TACs) because the trigeminal nerve (a major face-pain nerve) and the body’s automatic (autonomic) responses are both involved. ICHD-3

Attacks can come in bursts, and people may have many attacks in a day. The pain is moderate to severe, but each attack is brief. In many people, attacks cluster during the daytime and can be frequent—sometimes a few to dozens or even more per day. American Migraine Foundation

---

Types of SUNCT

Doctors use the International Classification of Headache Disorders (ICHD-3) to label SUNCT. Two useful ways to think about “type” are by pattern over time and by attack shape:

1. By pattern over time

• Episodic SUNCT: Attacks occur in periods (bouts) lasting 7 days to 1 year, separated by pain-free gaps of at least 3 months. ICHD-3

• Chronic SUNCT: Attacks happen for more than a year without a 3-month break, or with breaks shorter than 3 months. (This mirrors the ICHD-3 “chronic” definition for SUNCT within the TAC group.) ICHD-3

2. By attack shape (what a single attack looks like)
   ICHD-3 allows that the pain can come as single stabs, a series of stabs, or a “saw-tooth” pattern where pain ramps up and down quickly—still staying within seconds to a few minutes. These shapes feel different but are all SUNCT when the other features fit. ICHD-3

Note on SUNA: A closely related diagnosis is SUNA (short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms), where conjunctival redness and tearing are not both required. SUNCT and SUNA sit under the broader umbrella SUNHA and likely represent a spectrum, but this article focuses on SUNCT. LWW JournalsSAGE Journals

---

Causes

SUNCT can be primary (no clear structural cause—this is most common) or secondary (a structural or medical problem is driving the SUNCT-like attacks). Doctors always check for secondary causes because treating the underlying issue can help. Categories and examples below come from medical reviews of “secondary SUNCT.” PMCNCBI

1. Primary SUNCT (idiopathic): No visible structural cause on scans. The best theory is abnormal signaling in the trigeminal nerve and brainstem autonomic pathways that briefly “switch on” pain and eye/nose symptoms. (Primary SUNCT is a diagnosis made after proper testing rules out secondary causes.) ICHD-3

2. Pituitary adenoma: Benign pituitary tumors, including prolactinomas, can trigger SUNCT-like attacks; headache may improve when the tumor is treated. SAGE Journals

3. Other sellar/parasellar lesions: Cysts or other masses near the pituitary can irritate nearby pain pathways. SAGE Journals

4. Posterior fossa tumors: Lesions in the cerebellopontine angle (e.g., meningioma, vestibular schwannoma) are classic mimics and must be excluded. ICHD-3

5. Vascular compression of the trigeminal root: A looping artery (e.g., SCA or AICA) can compress the trigeminal nerve and provoke neuralgiform attacks with autonomic features. PMC

6. Arteriovenous malformation (AVM): Vascular tangles near trigeminal pathways may trigger SUNCT-like pain. PMC

7. Intracranial aneurysm: Rarely, aneurysms close to trigeminal structures can produce short, one-sided attacks. PMC

8. Multiple sclerosis plaques: Demyelinating lesions in the pons or trigeminal pathways can cause neuralgiform facial pain with autonomic signs. PMC

9. Brainstem inflammation: Autoimmune or infectious brainstem inflammation can irritate the trigeminal-autonomic circuits. PMC

10. Post-traumatic change: Head or facial trauma sometimes precedes the start of SUNCT-like attacks. PMC

11. Herpes zoster (shingles) affecting trigeminal nerve: Can lead to neuralgiform pain phenotypes with redness/tearing during attacks. PMC

12. Sinus or nasal cavity disease: Inflammatory disease near trigeminal branches can mimic SUNCT; careful ENT and imaging assessment helps separate them. PMC

13. Dental or jaw pathology: Rarely, tooth or temporomandibular problems can trigger short, unilateral pain spells that resemble SUNCT. PMC

14. Congenital malformations: Some people have structural variants near the trigeminal nerve from birth that can predispose to SUNCT-like attacks. PMC

15. Inflammatory granulomatous disease (e.g., sarcoidosis): Lesions in the skull base or leptomeninges can provoke neuralgiform pain. PMC

16. Meningeal processes (e.g., pachymeningitis): Thickening or inflammation around pain pathways may trigger attacks. PMC

17. Cerebrospinal fluid pressure disorders: Marked low or high CSF pressure can cause unusual headache syndromes that sometimes mimic TACs. (Clinicians consider this when features are atypical.) PMC

18. Diabetes-related neuropathy: Metabolic stress on small facial nerves can rarely create short stabbing pains with autonomic signs. PMC

19. Iatrogenic causes: Prior surgery or procedures near the trigeminal nerve can set up a neuralgiform pain state. PMC

20. Other brain tumors or cysts (e.g., epidermoid): Any lesion impinging on the trigeminal root entry zone can produce SUNCT-like attacks. PMC

---

Symptoms

Each symptom below is written in simple language. Not everyone has all of them, but most people have many of them during attacks.

1. Sudden, one-sided, stabbing or electric pain around the eye, temple, or forehead. It starts fast and stops fast. ICHD-3

2. Very short attack time: usually seconds and almost always under 5 minutes. American Migraine Foundation

3. Eye redness on the same side as the pain (the white of the eye turns red). ICHD-3

4. Tearing from the same eye during the attack. ICHD-3

5. Runny or stuffy nose on the same side as the pain. ICHD-3

6. Puffy eyelid on that side. ICHD-3

7. Facial sweating or flushing on that side. ICHD-3

8. Sensation of eyelid droop or fullness during the attack. ICHD-3

9. High attack frequency: from a few to dozens of attacks per day; bursts can occur many times in an hour. American Migraine Foundation

10. Daytime tendency: attacks often happen more in the day than at night. American Migraine Foundation

11. Triggers: light touch to the face or scalp, chewing, talking, brushing teeth, or washing the face can set off an attack; unlike classic trigeminal neuralgia, there may be little or no refractory period after an attack. PMC

12. Restlessness during attacks because the pain is sharp and disruptive. (This is typical in TACs.) Continuum

13. Short “series” or “saw-tooth” pain pattern: the pain can ramp up and down quickly or come as quick repeated jabs. ICHD-3

14. Occasional migraine-like features: some people report nausea, phonophobia, or throbbing, but these are usually milder than in migraine and the attacks remain very brief. LWW Journals

15. Normal feeling between attacks: in most people the face feels normal between attacks, especially in the episodic form. (This helps separate SUNCT from continuous neuralgia.)

---

Diagnostic Tests

Doctors make a SUNCT diagnosis mainly from the history and exam, then use tests to exclude look-alike conditions and to check for secondary causes such as pituitary or posterior fossa lesions. Below are 20 commonly used tests, grouped by type, each described in simple terms. ICHD-3NCBI

A) Physical exam

1. Focused neurological exam: The doctor checks cranial nerves (eye movements, facial feeling and strength, corneal reflex), coordination, and reflexes to make sure there are no persistent nerve deficits that would point to a mass or demyelinating disease rather than a pure attack-only syndrome. Continuum

2. Ocular surface inspection during an attack: If an attack is observed, the clinician looks for eye redness and tearing on the painful side, which are hallmark autonomic signs of SUNCT. ICHD-3

3. Nasal/face autonomic signs check: During or right after an attack, they look for runny or stuffy nose, sweating, flushing, and eyelid swelling on the same side, which support a TAC diagnosis. ICHD-3

4. Attack mapping: Using the history (and drawings if helpful), the clinician maps the exact pain location (orbit, supra-orbit, temple) and confirms it is strictly one-sided, aligning with ICHD-3 criteria. ICHD-3

5. Differential “red flag” screen: They check blood pressure, temperature, and a general exam to look for fever, immune problems, or other clues that point to infections, inflammation, or systemic disease requiring a different work-up. Continuum

B) Manual bedside/provocation tests

6. Trigger-zone testing: Gentle touch to common trigger areas (cheek, around the eye, scalp) or asking the person to chew or talk may provoke a brief attack, which supports SUNCT when combined with autonomic signs and very short duration. (Unlike classic trigeminal neuralgia, there is often no refractory period.) PMC

7. Jaw movement testing: The clinician asks the person to open/close the mouth or clench the teeth. If these movements set off a very brief, strictly one-sided attack with redness/tearing, it favors SUNCT over dental or TMJ causes. Continuum

8. Light/cold air or facial washing provocation (history-based): Reporting that cool air or washing the face can trigger seconds-long attacks helps steer toward SUNCT/SUNA vs. migraine (which usually lasts hours). American Migraine Foundation

9. Indomethacin trial (to exclude PH/hemicrania continua): A supervised trial of indomethacin (a specific anti-inflammatory) can help rule out other TACs that are classically indomethacin-responsive (like paroxysmal hemicrania); SUNCT typically is not. This is a diagnostic differentiation step, not a SUNCT treatment. American Migraine Foundation

C) Lab and pathological tests

10. Pituitary hormone panel: Blood tests for prolactin, IGF-1, TSH/free T4, morning cortisol, and sometimes LH/FSH look for pituitary disorders that can mimic SUNCT; abnormal results prompt targeted endocrine care. NCBI

11. Inflammation markers (ESR/CRP): Useful to screen for hidden inflammatory or infectious processes that could cause secondary neuralgiform pain. PMC

12. Basic metabolic panel and glucose: Metabolic derangements can aggravate neuralgic pain and are checked to rule out contributors, especially in older adults or those with diabetes. PMC

13. CBC: Looks for infection or blood disorders that, together with symptoms and imaging, might point to secondary causes needing treatment. PMC

14. Autoimmune screen in select cases: ANA or other targeted tests may be ordered when exam or history suggest systemic inflammation (e.g., sarcoidosis), which can involve the skull base or meninges. PMC

D) Electrodiagnostic tests

15. Blink reflex testing (trigeminal-facial reflex): Measures the integrity of the trigeminal and facial nerve loop. Abnormalities can hint at lesions affecting the trigeminal pathways rather than a purely primary SUNCT. Continuum

16. Trigeminal somatosensory evoked potentials (SSEPs): A research-adjacent test that evaluates sensory conduction through trigeminal pathways; considered when imaging and exam raise concern for demyelination or compressive lesions. Continuum

17. EEG (when spells look seizure-like): Very brief facial pain with autonomic signs is typical for SUNCT, but if episodes are atypical (altered awareness, automatisms), EEG helps rule out focal seizures mimicking pain attacks. Continuum

E) Imaging tests

18. MRI brain with and without contrast, with pituitary protocol: This is the minimum imaging most experts recommend. It examines the posterior fossa, trigeminal root entry zone, and the pituitary for tumors, inflammatory lesions, demyelination, or vascular compression. NCBIICHD-3

19. MRA/CTA (vascular imaging): Looks for aneurysms, AVMs, or arterial loops compressing the trigeminal nerve that can mimic or cause SUNCT-like attacks. PMC

20. High-resolution cranial nerve MRI (e.g., 3D CISS/FIESTA): Gives a fine-detail view of the trigeminal nerve and the cerebellopontine angle to spot subtle vascular contact or small masses that standard MRI might miss. ICHD-3

Non-pharmacological treatments (therapies & others)

(each with Description • Purpose • Mechanism)

1. Attack diary & pattern tracking
   Description: Note times, triggers, and duration daily.
   Purpose: Spot triggers and treatment effects.
   Mechanism: Identifies personal trigger patterns (e.g., shaving, face washing) to guide avoidance and timing of preventives.

2. Trigger-avoidance training
   Description: Learn gentle strategies around known trigger zones (e.g., using a soft cloth, touching from the non-painful side).
   Purpose: Cut attack frequency day-to-day.
   Mechanism: Reduces tactile input to hyper-excitable trigeminal endings.

3. Protective face/eye measures
   Description: Warm scarf in cold wind; wrap-around glasses for gusts.
   Purpose: Prevent cold/airflow triggers.
   Mechanism: Stabilizes temperature and mechanical stimulation on facial trigger zones.

4. Paced jaw and speech habits
   Description: Smaller bites, slow chewing; brief pauses while speaking.
   Purpose: Limit motion-triggered stabs.
   Mechanism: Lowers sudden proprioceptive input to trigeminal motor-sensory arcs.

5. Neck ergonomics & micro-breaks
   Description: Neutral neck posture; breaks from sustained flexion (screens/phones).
   Purpose: Prevent neck-related facilitation of face triggers.
   Mechanism: Eases cervico-trigeminal cross-sensitization.

6. Sleep regularity
   Description: Consistent bed/wake times; dark, quiet bedroom.
   Purpose: Improve brain pain-control thresholds.
   Mechanism: Stabilizes hypothalamic rhythms tied to TAC disorders.

7. Stress-reduction routines
   Description: Daily 10–15 minutes of breathing, mindfulness, or brief CBT skills.
   Purpose: Lower fight-or-flight arousal that can set off bursts.
   Mechanism: Boosts top-down inhibition of trigeminal pain circuits.

8. Heat or cool packs (brief, gentle)
   Description: Short applications around—not on—the trigger spot.
   Purpose: Distract and sometimes dampen mild bursts.
   Mechanism: Competes with nociceptive signals via gate-control on the skin.

9. Hydration rhythm
   Description: Small, frequent water intake through the day.
   Purpose: Avoid dehydration-related irritability of pain networks.
   Mechanism: Prevents systemic stressors that lower thresholds.

10. Caffeine moderation
    Description: Keep total caffeine steady (avoid big swings).
    Purpose: Prevent rebound sensitivity from caffeine spikes/crashes.
    Mechanism: Smooths adenosine-related vascular and neuronal effects.

11. Greater occipital nerve block (GONB)
    Description: Outpatient injection near the occipital nerve with anesthetic ± steroid.
    Purpose: Temporary reduction of attack load in some patients.
    Mechanism: Modulates pain traffic in trigemino-cervical complex; success rates are modest in SUNCT compared with other TACs. JNNP

12. Sphenopalatine ganglion (SPG) block
    Description: Local anesthetic via intranasal applicator; sometimes pulsed RF in refractory cases.
    Purpose: Abort or reduce clusters of attacks in selected patients.
    Mechanism: Dampens a key parasympathetic relay in TACs; small SUNCT/SUNA series show benefit. PubMed+1

13. Gentle facial desensitization
    Description: Stepwise exposure with ultra-light touch under therapist guidance.
    Purpose: Reduce allodynia to daily stimuli.
    Mechanism: Gradual recalibration of peripheral sensory thresholds.

14. Physiotherapy for cervicogenic contributors
    Description: Upper-cervical mobility, scapular control, and postural drills.
    Purpose: Remove neck amplifiers of facial pain.
    Mechanism: Decreases nociceptive input to the trigemino-cervical junction.

15. Blue-light hygiene & screen pacing
    Description: Use night-shift filters; 20-20-20 eye breaks.
    Purpose: Reduce visual strain that can lower attack thresholds.
    Mechanism: Limits sustained trigeminal/ocular stress.

16. Nerve-friendly daily routine
    Description: Schedule face-triggering tasks (shaving, flossing) when attacks are least likely for you.
    Purpose: Minimize provoked bursts.
    Mechanism: Aligns behavior to personal trigger windows.

17. Mind-body pain coping skills
    Description: Brief CBT/ACT skills for fear of triggers, pacing, and resilience.
    Purpose: Lower distress and avoidance cycles.
    Mechanism: Rebuilds top-down control over pain networks.

18. Workplace/School accommodations
    Description: Flexible breaks; ergonomic setup; permission for protective eyewear.
    Purpose: Sustain participation without flares.
    Mechanism: Removes environmental triggers.

19. Peer support & education
    Description: Rare-disease groups (with clinician moderation).
    Purpose: Practical tips and adherence gains.
    Mechanism: Social learning and self-efficacy.

20. Headache specialist follow-up plan
    Description: Pre-agreed steps for flares (who to call, when to use bridge therapy).
    Purpose: Faster control; fewer ER visits.
    Mechanism: Timely escalation (e.g., lidocaine bridge) before sensitization escalates. JNNP

---

Drug treatments

Doses below are typical ranges used in studies/clinical practice for adults. Your doctor will individualize dosing, check interactions, and monitor labs.

1. Lamotrigine
   Class: Anticonvulsant (voltage-gated sodium channel blocker; glutamate modulation).
   Dose: Start 25 mg daily; slowly titrate to 100–400 mg/day (often 200–300 mg/day), divided.
   Timing: Preventive; takes days–weeks as you titrate.
   Purpose: First-line daily prevention; reduces attack frequency/severity in many.
   Mechanism: Stabilizes hyper-excitable trigeminal neurons and central pain networks.
   Side effects: Rash (rare SJS risk—slow titration), dizziness, nausea, insomnia. PubMed+1Oxford Academic

2. Topiramate
   Class: Anticonvulsant (sodium channel, GABA, glutamate, carbonic anhydrase effects).
   Dose: Start 25 mg nightly; titrate to 50–200 mg/day.
   Timing: Preventive.
   Purpose: Second-line daily prevention.
   Mechanism: Lowers neuronal excitability across multiple channels.
   Side effects: Tingling, cognitive slowing/word-finding difficulty, weight loss, kidney stones. PMC

3. Oxcarbazepine
   Class: Anticonvulsant (sodium channel blocker).
   Dose: 150–300 mg twice daily; target 600–1,200 mg/day.
   Timing: Preventive; sometimes combined with gabapentin.
   Purpose: Alternative to carbamazepine with better tolerability for some.
   Mechanism: Dampens ectopic trigeminal firing.
   Side effects: Drowsiness, dizziness, hyponatremia; drug interactions. PMCOxford Academic

4. Gabapentin
   Class: α2δ calcium-channel modulator.
   Dose: 300 mg nightly → 900–2,400 mg/day in divided doses.
   Timing: Preventive.
   Purpose: Reduce daily attack load; useful add-on.
   Mechanism: Lowers excitatory neurotransmission in trigeminal pathways.
   Side effects: Sedation, dizziness, edema. PMC

5. Pregabalin
   Class: α2δ calcium-channel modulator.
   Dose: 50–75 mg twice daily → 150–300 mg/day.
   Timing: Preventive/add-on.
   Purpose: Similar rationale to gabapentin; sometimes better tolerated.
   Mechanism: Cuts calcium-dependent neurotransmitter release.
   Side effects: Drowsiness, weight gain, edema. PMC

6. Carbamazepine
   Class: Anticonvulsant (sodium channel blocker).
   Dose: 100 mg twice daily → 400–800 mg/day.
   Timing: Preventive in selected cases.
   Purpose: Classic trigeminal neuralgia drug; variable/less robust benefit in SUNCT.
   Mechanism: Stabilizes neuronal membranes.
   Side effects: Dizziness, hyponatremia, rash, hepatic/hematologic monitoring needed. PubMed

7. Intravenous Lidocaine (monitored bridge therapy)
   Class: Sodium channel blocker (local anesthetic given IV).
   Dose: Continuous infusion ~1.3–3.3 mg/kg/hour for several days in a monitored setting.
   Timing: Transitional—for severe flares or while a preventive is being titrated.
   Purpose: Temporarily turns off attacks; buys time.
   Mechanism: Silences hyper-excitable trigeminal circuits.
   Side effects: Requires ECG/BP monitoring; potential arrhythmia, perioral numbness, metallic taste, dizziness. PubMedJNNPNCBI

8. Mexiletine (oral)
   Class: Oral sodium channel blocker (antiarrhythmic).
   Dose: 150–200 mg 2–3×/day (specialist use).
   Timing: Preventive for refractory cases.
   Purpose: Maintains sodium-channel blockade after IV lidocaine or as a trial.
   Mechanism: Similar to lidocaine but oral.
   Side effects: GI upset, tremor, arrhythmia risk—cardiology oversight advised. (Evidence mainly case-based.)

9. Phenytoin / Fosphenytoin (IV, selected cases)
   Class: Sodium channel blocker anticonvulsant.
   Dose: Standard IV loading (e.g., 15–20 mg/kg) in monitored settings.
   Timing: Rescue when IV lidocaine is unavailable/contraindicated.
   Purpose: Short-term attack suppression.
   Mechanism: Limits high-frequency neuronal firing.
   Side effects: Cardiac/ BP effects (fosphenytoin safer IV), nystagmus, ataxia. (Evidence limited.)

10. Botulinum toxin A (off-label, selective)
    Class: Neuromuscular/neuronal release blocker.
    Dose: Patterned injections per headache protocol every ~12 weeks.
    Timing: Preventive in refractory SUNCT/SUNHA.
    Purpose: Reduce peripheral input and central sensitization.
    Mechanism: Blocks peripheral neurotransmitter release; downstream central effects.
    Side effects: Local pain, eyebrow/eyelid droop if misplaced. (Use guided by expert centers; evidence emerging.) PubMed

A note on acute SUNCT: Because attacks are seconds long, typical acute migraine/cluster medicines (triptans, oxygen) usually cannot act fast enough; studies report little benefit in SUNCT, even when oxygen is delivered at effective cluster-headache doses. This difference helps distinguish SUNCT from cluster headache. PMC

---

Dietary molecular supplements

These are adjuncts. None are proven SUNCT cures. Discuss with your clinician, especially if pregnant, on blood thinners, or with kidney/liver disease.

1. Magnesium (citrate/ glycinate)
   Dose: 200–400 mg elemental/day.
   Function: Calms nerve excitability; supports energy metabolism.
   Mechanism: NMDA receptor modulation; stabilizes neuronal membranes.

2. Riboflavin (Vitamin B2)
   Dose: 200–400 mg/day.
   Function: Mitochondrial support; used in migraine prevention.
   Mechanism: Improves cellular energy handling in neurons.

3. Coenzyme Q10
   Dose: 100–300 mg/day with food.
   Function: Mitochondrial electron transport; antioxidant.
   Mechanism: Enhances ATP production; reduces oxidative stress.

4. Melatonin (night)
   Dose: 3–10 mg 1–2 hours before sleep.
   Function: Sleep regularity; TACs are hypothalamus-linked.
   Mechanism: Regulates circadian biology; possible anti-nociceptive effects.

5. Omega-3 EPA/DHA
   Dose: 1–2 g combined EPA+DHA/day.
   Function: Anti-inflammatory lipid balance; neural membrane health.
   Mechanism: Resolvin pathway; membrane fluidity.

6. Alpha-lipoic acid
   Dose: 300–600 mg/day.
   Function: Neuropathic-pain support; antioxidant.
   Mechanism: Reduces oxidative and inflammatory signaling.

7. Palmitoylethanolamide (PEA)
   Dose: 400–600 mg twice daily.
   Function: Endogenous fatty-acid amide; analgesic/anti-inflammatory in neuropathic pain.
   Mechanism: PPAR-α activation; mast-cell modulation.

8. Vitamin D3
   Dose: As guided by level (often 1,000–2,000 IU/day if low).
   Function: Immune and neural support.
   Mechanism: Gene regulation in immune/neuronal cells.

9. Curcumin (with piperine or phytosome)
   Dose: 500–1,000 mg/day standardized extract.
   Function: Anti-inflammatory adjunct.
   Mechanism: NF-κB and COX-2 pathway modulation.

10. Acetyl-L-carnitine
    Dose: 1,000–2,000 mg/day in divided doses.
    Function: Nerve metabolism support; used in some neuropathic conditions.
    Mechanism: Mitochondrial fatty-acid transport; neurotrophic effects.

---

Regenerative / stem-cell drugs

There are no approved or proven “immunity boosters,” regenerative drugs, or stem-cell treatments for SUNCT. Using such products outside a regulated clinical trial can be risky and expensive without benefit. What is used in advanced, refractory SUNCT are neuromodulation procedures (ONS, MVD, DBS, SPG interventions) under specialist care—not “immune” or “stem-cell” drugs. PubMed+2PubMed+2PMC

To align with your requested format, here are six categories often marketed online—with the medically accurate status:

1. CGRP monoclonal antibodies (erenumab, fremanezumab, etc.)
   Dosage: Approved for migraine (monthly/quarterly), not for SUNCT.
   Function/mechanism: Block CGRP signaling to reduce migraine susceptibility.
   Status in SUNCT: No solid evidence; off-label use is experimental and should be specialist-guided only.

2. Stem-cell infusions (mesenchymal cells, etc.)
   Dosage: None established for SUNCT.
   Function/mechanism: Theoretical tissue repair/immune modulation.
   Status: Not recommended outside trials; no evidence of benefit in SUNCT; potential risks.

3. “Immune boosters” (interferons, thymic peptides, IVIG for SUNCT)
   Dosage: None established for SUNCT.
   Mechanism: Broad immune modulation.
   Status: No evidence for SUNCT; could cause harm; avoid unless a specialist identifies a specific immune disease cause.

4. Nerve-growth factor or BDNF-targeting agents
   Dosage: None for SUNCT.
   Mechanism: Neurotrophic modulation.
   Status: Experimental neuroscience—no clinical role in SUNCT.

5. Nav1.7-selective channel blockers (investigational)
   Dosage: Trial-only.
   Mechanism: Pain-fiber sodium-channel blockade.
   Status: Research-stage; not available for routine care.

6. Cannabinoid pharmaceuticals
   Dosage: Varies by indication; no dosing established for SUNCT.
   Mechanism: CB1/CB2 modulation of pain pathways.
   Status: Evidence insufficient in SUNCT; if considered, do so only under medical supervision, mindful of legal status and side effects.

---

Surgeries/procedures

1. Occipital Nerve Stimulation (ONS)
   Procedure: Thin leads are placed under the skin over the greater occipital nerves and connected to a pulse generator (like a pacer).
   Why: For medically intractable SUNCT/SUNA, ONS can reduce attack burden with relatively low anatomic risk and without destroying nerves. Evidence shows meaningful benefit in many refractory cases. PubMedPain PhysicianPMC

2. Microvascular Decompression (MVD) of the trigeminal nerve
   Procedure: Neurosurgery behind the ear lifts a small artery/vein off the trigeminal root and inserts a cushion (Teflon) to stop pulsatile contact.
   Why: When high-resolution MRI shows likely neurovascular compression, MVD can provide long-term relief in selected SUNCT/SUNA patients. PMC

3. Deep Brain Stimulation (DBS) of the posterior hypothalamus
   Procedure: An electrode is stereotactically implanted into the posterior hypothalamic region and connected to an implanted generator.
   Why: Considered only in highly refractory TACs (including SUNCT) at expert centers; case reports/series suggest benefit. PubMed+1

4. Sphenopalatine Ganglion (SPG) procedures
   Procedure: From office-based blocks to pulsed radiofrequency or implantable stimulators (cluster data stronger than SUNCT).
   Why: Targets a key parasympathetic hub; small SUNCT/SUNA series show promise in refractory cases. PubMed

5. Destructive trigeminal procedures (radiofrequency rhizotomy, Gamma Knife)
   Procedure: Lesioning portions of the trigeminal pathway.
   Why: Rarely used now because outcomes are variable and risks include numbness and deafferentation pain; generally not first-choice for SUNCT. (Specialist discretion only.) PubMed

---

Prevention tips

1. Keep sleep regular—same bed/wake times.

2. Identify and avoid personal triggers (touch, cold wind, jaw overuse).

3. Use protective eyewear/scarf in wind or cold.

4. Pace chewing/talking; smaller bites; soft foods during bad periods.

5. Take screen/neck breaks; keep the neck neutral.

6. Hydrate steadily; avoid big caffeine swings.

7. Manage stress with brief daily relaxation.

8. Plan face-touching tasks (shaving, flossing) at your “quiet” time.

9. Stick to your preventive medication plan and titration.

10. Have a flare plan with your specialist (including if/when to use IV lidocaine as a bridge). JNNP

---

When to see a doctor urgently

• First-ever SUNCT-like pain or a major change in your pattern.

• Neurologic signs: double vision, facial numbness/weakness, confusion.

• Red flags: fever, stiff neck, cancer, immune suppression, pregnancy with new severe head pain.

• **Eye red and painful with vision loss (could be an eye emergency).

• No improvement after proper medicine trials, or worsening despite treatment.

• Head injury before symptoms began.

• Severe, frequent bursts that need bridge therapy (consider monitored IV lidocaine). JNNP

---

What to eat and what to avoid

What to eat

1. Magnesium-rich foods: leafy greens, legumes, nuts, seeds.

2. Omega-3 sources: fish (salmon, sardines), walnuts, flax.

3. Steady complex carbs: whole grains to avoid energy dips.

4. Hydrating choices: water, herbal teas; small, regular sips.

5. B-vitamin sources: eggs, dairy/yogurt, mushrooms, greens.

What to avoid or limit

1. Alcohol, especially near your usual attack window.
2. Very cold foods/drinks that can trigger facial sensitivity.
3. Excess caffeine or big caffeine swings.
4. MSG/ultra-processed foods if you notice they trigger you.
5. Skipped meals (energy crashes can lower thresholds).

---

Frequently asked questions

1) Is SUNCT the same as cluster headache?
No. Both are TACs (one-sided with autonomic signs), but SUNCT attacks are much shorter (seconds) and oxygen/triptans usually don’t help, unlike cluster. PMC

2) How is SUNCT different from paroxysmal hemicrania?
Paroxysmal hemicrania often stops with indomethacin; SUNCT typically doesn’t. PubMed

3) What is the best daily medicine?
Many specialists start with lamotrigine; others add or switch to topiramate, oxcarbazepine, or gabapentin based on response and side effects. PubMedPMC

4) What if my attacks explode suddenly?
A monitored IV lidocaine infusion can quiet the system for days while your preventive is optimized. PubMedJNNP

5) Are nerve blocks helpful?
Occipital or sphenopalatine ganglion blocks can help some people, but results vary in SUNCT. JNNPPubMed

6) Is surgery a cure?
If imaging shows neurovascular contact, MVD can help selected patients; otherwise ONS or, rarely, DBS may reduce attacks. These are for refractory cases at expert centers. PMCPubMed

7) Do triptans or oxygen work?
Not usually for SUNCT (attacks are too brief); they are more for cluster headache. PMC

8) Can supplements replace medication?
No. Some supplements support nerve health or sleep, but medicines and procedures carry the strongest evidence for SUNCT control.

9) Is SUNCT dangerous?
It’s not life-threatening, but the pain can be disabling. Medical review is vital to exclude secondary causes and plan care.

10) What brings on attacks?
Often light touch or movement of the face/jaw, cold wind, or neck strain. Mapping your triggers helps.

11) Will SUNCT go away?
Course varies. Some have episodic periods with remissions; others have chronic patterns. Good preventive care often reduces attacks.

12) Can stress cause SUNCT?
Stress doesn’t cause SUNCT but can lower your trigger threshold. Daily stress-reduction helps.

13) Is there a test that proves SUNCT?
No single lab test. Diagnosis relies on ICHD-3 criteria, history, exam, and MRI to rule out other causes. ICHD-3

14) Are there children with SUNCT?
Yes, but it’s rare; pediatric series exist using ICHD-3 guidance adapted for kids. PubMed

15) What if nothing works?
Seek a tertiary headache center. Options include combined preventives, procedural therapies (SPG interventions, ONS), and in very select cases MVD or DBS. PubMed+1PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 26, 2025.